Smith Lynette M, Gallagher J Christopher, Suiter Corinna
Biostatistics, Public Health Department, University Nebraska Medical Center, Omaha, NE 68198, United States.
Endocrinology, Creighton University Medical School, Omaha, NE 68131, United States.
J Steroid Biochem Mol Biol. 2017 Oct;173:317-322. doi: 10.1016/j.jsbmb.2017.03.015. Epub 2017 Mar 18.
Falls are a serious health problem in the aging population. Because low levels of vitamin D have been associated with increased fall rates, many trials have been performed with vitamin D; two meta-analyses showed either a small effect or no effect of vitamin D on falls. We conducted a study of the effect of vitamin D on serum 25 hydroxyvitamin D (25OHD) and data on falls was collected as a secondary outcome. In a 12-month double blind randomized placebo trial, elderly women, mean age 66 years, were randomized to one of seven daily oral doses of vitamin D or placebo. The main inclusion criterion for study was a baseline serum 25OHD<20ng/ml (50nmol/L). A history of falls was collected at baseline and fall events were collected every 3 months. Results showed that the effect of vitamin D on falls followed a U-shaped curve whether analyzed by dose or serum 25OHD levels. There was no decrease in falls on low vitamin D doses 400, 800 IU, a significant decrease on medium doses 1600, 2400,3200 IU (p=0.020) and no decrease on high doses 4000, 4800 IU compared to placebo (p=0.55). When compared to 12-month serum 25OHD quintiles, the faller rate was 60% in the lowest quintile <25ng/ml (<50nmol/L), 21% in the low middle quintile 32-38ng/ml (80-95nmo/L), 72% in the high middle quintile 38-46ng/ml (95-115nmo/L) and 45% in the highest quintile 46-66ng/ml (115-165nmol/L). In the subgroup with a fall history, fall rates were 68% on low dose, 27% on medium doses and 100% on higher doses. Fall rates on high doses were increased compared to medium doses (Odds Ratio 5.6.95% CI: 2.1-14.8). In summary, the maximum decrease in falls corresponds to a 12- month serum 25OHD of 32-38ng/ml (80-95nmol/L) and faller rates increase as serum 25OHD exceed 40-45ng/ml (100-112.5nmol/L). The Tolerable upper limit (TUL) recently increased in 2010 from 2000 to 4000 IU/day may need to be reduced in elderly women especially in those with a fall history.
跌倒在老年人群中是一个严重的健康问题。由于低水平的维生素D与跌倒发生率增加有关,因此针对维生素D进行了许多试验;两项荟萃分析显示维生素D对跌倒的影响很小或没有影响。我们开展了一项关于维生素D对血清25羟维生素D(25OHD)影响的研究,并将跌倒数据作为次要结果进行收集。在一项为期12个月的双盲随机安慰剂试验中,平均年龄为66岁的老年女性被随机分配至七种每日口服剂量的维生素D或安慰剂中的一种。研究的主要纳入标准是基线血清25OHD<20ng/ml(50nmol/L)。在基线时收集跌倒病史,并每3个月收集一次跌倒事件。结果显示,无论按剂量还是血清25OHD水平分析,维生素D对跌倒的影响呈U形曲线。低剂量400、800 IU的维生素D对跌倒没有降低作用,中等剂量1600、2400、3200 IU时有显著降低(p=0.020),而高剂量4000、4800 IU与安慰剂相比没有降低作用(p=0.55)。与12个月时血清25OHD五分位数相比,跌倒发生率在最低五分位数<25ng/ml(<50nmol/L)时为60%,低中五分位数32 - 38ng/ml(80 - 95nmol/L)时为21%,高中五分位数38 - 46ng/ml(95 - 115nmol/L)时为72%,最高五分位数46 - 66ng/ml(115 - 165nmol/L)时为45%。在有跌倒病史的亚组中,低剂量时跌倒发生率为68%,中等剂量时为27%,高剂量时为100%。高剂量时的跌倒发生率与中等剂量相比有所增加(优势比5.6,95%置信区间:2.1 - 14.8)。总之,跌倒减少最多对应的12个月血清25OHD水平为32 - 38ng/ml(80 - 95nmol/L),当血清25OHD超过40 - 45ng/ml(100 - 112.5nmol/L)时跌倒发生率增加。2010年最近将可耐受上限(TUL)从每日2000 IU提高到了4000 IU,对于老年女性,尤其是有跌倒病史的老年女性,可能需要降低这一上限。